Histone deacetylase 3 (HDAC3) inhibitors as anticancer agents: A review

R Sarkar, S Banerjee, SA Amin, N Adhikari… - European journal of …, 2020 - Elsevier
Abstract Among different Histone deacetylases (HDACs), histone deacetylase 3 (HDAC3) is
an epigenetic drug target which is currently marked as a potential therapeutic strategy to …

Binary quantitative activity-activity relationship (QAAR) studies to explore selective HDAC8 inhibitors: In light of mathematical models, DFT-based calculation and …

SA Amin, J Kumar, S Khatun, S Das, IA Qureshi… - Journal of Molecular …, 2022 - Elsevier
Abstract Histone deacetylase 8 (HDAC8) selectivity over other HDACs is a major concern of
interest, since HDAC8 has been implicated as a potential drug target of many diseases …

Quantitative activity–activity relationship (QAAR) driven design to develop hydroxamate derivatives of pentanoic acids as selective HDAC8 inhibitors: synthesis …

SA Amin, P Trivedi, N Adhikari, G Routholla… - New Journal of …, 2021 - pubs.rsc.org
Histone deacetylase 8 (HDAC8) has been implicated as a potential drug target of many
diseases including cancer. HDAC8 isoform selectivity over other class-I HDACs is a major …

Medicinal chemistry of histone deacetylase inhibitors

D Ružić, N Đoković, K Nikolić, Z Vujić - Arhiv za farmaciju, 2021 - farfar.pharmacy.bg.ac.rs
Today, we are witnessing an explosion of scientific concepts in cancer chemotherapy. It has
been considered for a long time that genetic instability in cancer should be treated with …